SELLAS Life Sciences Group, Inc.
(NASDAQ : SLS)

( )
SLS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.12%200.811.2%$402.10m
GILDGilead Sciences, Inc.
0.01%72.790.9%$394.52m
CELGCelgene Corporation
0.18%87.361.2%$339.76m
BIIBBiogen Inc.
-1.26%334.401.2%$273.97m
ILMNIllumina, Inc.
-1.67%347.223.5%$252.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.45%386.492.6%$210.24m
EXASExact Sciences Corporation
0.00%73.3325.3%$198.68m
VRTXVertex Pharmaceuticals Incorporated
-1.79%175.801.9%$159.87m
SRPTSarepta Therapeutics, Inc.
-0.27%152.3516.4%$124.87m
AAgilent Technologies, Inc.
0.33%69.081.5%$121.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.33%117.812.0%$107.50m
ALNYAlnylam Pharmaceuticals, Inc
-3.90%93.359.7%$95.81m
NKTRNektar Therapeutics
-1.48%57.455.6%$94.55m
BMRNBioMarin Pharmaceutical Inc.
-1.27%98.154.4%$90.68m
INCYIncyte Corporation
-1.57%67.022.5%$87.71m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.